<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292082</url>
  </required_header>
  <id_info>
    <org_study_id>2014-018</org_study_id>
    <nct_id>NCT02292082</nct_id>
  </id_info>
  <brief_title>The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)</brief_title>
  <acronym>ACB PAI</acronym>
  <official_title>The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee replacement is associated with severe post-operative pain. The purpose of this
      study is to compare two methods of treatment for pain control following Total Knee
      Replacement with an accelerated physical therapy protocol to aid the achievement of rehab
      milestones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 106 patients undergoing total knee arthroplasty will be randomized into two
      groups: one to receive only Periarticular injections and the other periarticular injections
      AND adductor canal block.

      Patients will be asked their numeric pain scores before surgery as baseline and at 24 and 48
      hours post-operation. Patients also will be asked questions from painOUT questionnaire at 24
      and 48 hours.

      Time to reach discharge criteria based on physical therapy assessments will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Meet Physical Therapy Discharge Criteria</measure>
    <time_frame>First 3 days post-operatively</time_frame>
    <description>Time to reach physical therapy (PT) goals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale (NRS) Pain Scores With Ambulation Postoperative Day 1</measure>
    <time_frame>24 hours after operating room discharge</time_frame>
    <description>Patient reported pain scores on postoperative day 1 from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score With Movement POD2</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>NRS pain with movement as reported by the patient. Rated from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption Postoperative Day (POD) 1</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Opioid consumption for patients from 0-24 hours postoperative, measured in mg OME (oral morphine equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption POD2</measure>
    <time_frame>24-48 hours postoperative</time_frame>
    <description>Opioid consumption over hours 24-48 postoperatively. Measured in mg OME (oral morphine equivalents). Higher equates to more opioids consumed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Average of 3 days</time_frame>
    <description>Measured in minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome Questionnaire (painOUT) Least Pain for 0-24 Hours Postoperatively</measure>
    <time_frame>Participants will be followed for the duration of 2 days post operatively in the hospital</time_frame>
    <description>Measures: least pain in the last 24 hours. Scores are measured from 0-10. 0 being no pain to 10 being the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome Questionnaire (painOUT) Least Pain for 24-48 Hours Postoperatively</measure>
    <time_frame>24-48 hours postoperative</time_frame>
    <description>Least pain experienced from 24-48 hours postoperative on a scale from 0-10. 0 being no pain at all to 10 being the worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome Questionnaire (painOUT) Most Pain for 0-24 Hours Postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Painout most pain experienced 0-24 hours postoperatively, measured from 0-10. 0 being no pain to 10 being the worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Outcome Questionnaire (painOUT) Most Pain for 24-48 Hours Postoperatively</measure>
    <time_frame>24-48 hours postoperative</time_frame>
    <description>Painout most pain experienced 24-48 hours postoperatively measured on a scale from 0-10. Higher scores indicate higher pain levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Society Score (KSS) at 6 Weeks Postoperatively</measure>
    <time_frame>Post operatively at approximately 6 weeks after surgery</time_frame>
    <description>KSS (Knee Society Score) score measured at 6 weeks postoperatively. The scale is from 0-100. Scores below 60 indicate poor function, 60-69 indicate fair, 70-79 indicate good, and 80-100 indicate excellent functional scores. KSS measures knee pain, flexion contracture,extension lag, alignment, stability, and total range of flexion and generates an associated score correlating to knee function. Higher is better. There is no sub score - only the cumulative Knee Society Score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o'clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
    <arm_group_label>Peri-Articular Injections only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>8 MHz. Chiba needle, 22 G / 4 inches</intervention_name>
    <arm_group_label>Peri-Articular Injections and Adductor Canal Block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteoarthritis scheduled for primary tricompartmental total knee
             arthroplasty with a participating surgeon

          -  Age 18 to 80 years

          -  Planned use of regional anesthesia

          -  Ability to follow study protocol

          -  English speaking (secondary outcomes include questionnaires validated in English only)

        Exclusion Criteria:

        Hepatic or renal insufficiency Patients younger than 18 years old and older than 80
        Patients intending to receive general anesthesia Patients planning to go to rehab post
        operatively Patients scheduled to go into the OR after 1 pm Allergy or intolerance to one
        of the study medications Patients with an ASA of IV Chronic gabapentin/pregabalin use
        (regular use for longer than 3 months) Chronic opioid use (taking opioids for longer than 3
        months) Diabetes Patients on workers compensation or disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique A Goytizolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <results_first_submitted>August 1, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nerve Block</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Knee Replacement, Total</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02292082/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02292082/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Peri-Articular Injections Only</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
        </group>
        <group group_id="P2">
          <title>Peri-Articular Injections and Adductor Canal Block</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peri-Articular Injections Only</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
        </group>
        <group group_id="B2">
          <title>Peri-Articular Injections and Adductor Canal Block</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="9.6"/>
                    <measurement group_id="B2" value="66.9" spread="6.6"/>
                    <measurement group_id="B3" value="65.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Meet Physical Therapy Discharge Criteria</title>
        <description>Time to reach physical therapy (PT) goals</description>
        <time_frame>First 3 days post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meet Physical Therapy Discharge Criteria</title>
          <description>Time to reach physical therapy (PT) goals</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2109.3" spread="1232.8"/>
                    <measurement group_id="O2" value="1883.1" spread="846.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numerical Rating Scale (NRS) Pain Scores With Ambulation Postoperative Day 1</title>
        <description>Patient reported pain scores on postoperative day 1 from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
        <time_frame>24 hours after operating room discharge</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (NRS) Pain Scores With Ambulation Postoperative Day 1</title>
          <description>Patient reported pain scores on postoperative day 1 from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.6"/>
                    <measurement group_id="O2" value="3.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score With Movement POD2</title>
        <description>NRS pain with movement as reported by the patient. Rated from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
        <time_frame>48 hours after surgery</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score With Movement POD2</title>
          <description>NRS pain with movement as reported by the patient. Rated from 0-10. 0 being no pain, 10 being the worst pain imaginable.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.6"/>
                    <measurement group_id="O2" value="5.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption Postoperative Day (POD) 1</title>
        <description>Opioid consumption for patients from 0-24 hours postoperative, measured in mg OME (oral morphine equivalents)</description>
        <time_frame>0-24 hours postoperatively</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption Postoperative Day (POD) 1</title>
          <description>Opioid consumption for patients from 0-24 hours postoperative, measured in mg OME (oral morphine equivalents)</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>mg OME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" spread="37.8"/>
                    <measurement group_id="O2" value="47.5" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption POD2</title>
        <description>Opioid consumption over hours 24-48 postoperatively. Measured in mg OME (oral morphine equivalents). Higher equates to more opioids consumed.</description>
        <time_frame>24-48 hours postoperative</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption POD2</title>
          <description>Opioid consumption over hours 24-48 postoperatively. Measured in mg OME (oral morphine equivalents). Higher equates to more opioids consumed.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>mg OME</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="49.1"/>
                    <measurement group_id="O2" value="60.1" spread="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Measured in minutes.</description>
        <time_frame>Average of 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Measured in minutes.</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3491" spread="1151.7"/>
                    <measurement group_id="O2" value="3394.4" spread="945.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Outcome Questionnaire (painOUT) Least Pain for 0-24 Hours Postoperatively</title>
        <description>Measures: least pain in the last 24 hours. Scores are measured from 0-10. 0 being no pain to 10 being the worst pain imaginable.</description>
        <time_frame>Participants will be followed for the duration of 2 days post operatively in the hospital</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Outcome Questionnaire (painOUT) Least Pain for 0-24 Hours Postoperatively</title>
          <description>Measures: least pain in the last 24 hours. Scores are measured from 0-10. 0 being no pain to 10 being the worst pain imaginable.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.8"/>
                    <measurement group_id="O2" value="0.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Outcome Questionnaire (painOUT) Least Pain for 24-48 Hours Postoperatively</title>
        <description>Least pain experienced from 24-48 hours postoperative on a scale from 0-10. 0 being no pain at all to 10 being the worst pain imaginable</description>
        <time_frame>24-48 hours postoperative</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Outcome Questionnaire (painOUT) Least Pain for 24-48 Hours Postoperatively</title>
          <description>Least pain experienced from 24-48 hours postoperative on a scale from 0-10. 0 being no pain at all to 10 being the worst pain imaginable</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.5"/>
                    <measurement group_id="O2" value="1.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Outcome Questionnaire (painOUT) Most Pain for 0-24 Hours Postoperatively</title>
        <description>Painout most pain experienced 0-24 hours postoperatively, measured from 0-10. 0 being no pain to 10 being the worst pain imaginable</description>
        <time_frame>0-24 hours postoperatively</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Outcome Questionnaire (painOUT) Most Pain for 0-24 Hours Postoperatively</title>
          <description>Painout most pain experienced 0-24 hours postoperatively, measured from 0-10. 0 being no pain to 10 being the worst pain imaginable</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="2.5"/>
                    <measurement group_id="O2" value="5.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Outcome Questionnaire (painOUT) Most Pain for 24-48 Hours Postoperatively</title>
        <description>Painout most pain experienced 24-48 hours postoperatively measured on a scale from 0-10. Higher scores indicate higher pain levels.</description>
        <time_frame>24-48 hours postoperative</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Outcome Questionnaire (painOUT) Most Pain for 24-48 Hours Postoperatively</title>
          <description>Painout most pain experienced 24-48 hours postoperatively measured on a scale from 0-10. Higher scores indicate higher pain levels.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.3"/>
                    <measurement group_id="O2" value="6.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Society Score (KSS) at 6 Weeks Postoperatively</title>
        <description>KSS (Knee Society Score) score measured at 6 weeks postoperatively. The scale is from 0-100. Scores below 60 indicate poor function, 60-69 indicate fair, 70-79 indicate good, and 80-100 indicate excellent functional scores. KSS measures knee pain, flexion contracture,extension lag, alignment, stability, and total range of flexion and generates an associated score correlating to knee function. Higher is better. There is no sub score - only the cumulative Knee Society Score.</description>
        <time_frame>Post operatively at approximately 6 weeks after surgery</time_frame>
        <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
        <group_list>
          <group group_id="O1">
            <title>Peri-Articular Injections Only</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
          </group>
          <group group_id="O2">
            <title>Peri-Articular Injections and Adductor Canal Block</title>
            <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Society Score (KSS) at 6 Weeks Postoperatively</title>
          <description>KSS (Knee Society Score) score measured at 6 weeks postoperatively. The scale is from 0-100. Scores below 60 indicate poor function, 60-69 indicate fair, 70-79 indicate good, and 80-100 indicate excellent functional scores. KSS measures knee pain, flexion contracture,extension lag, alignment, stability, and total range of flexion and generates an associated score correlating to knee function. Higher is better. There is no sub score - only the cumulative Knee Society Score.</description>
          <population>Unable to gather outcome data from all patients due to various reasons (exclusions, withdrawals, discharge, logistical reasons)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" spread="20"/>
                    <measurement group_id="O2" value="75.2" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peri-Articular Injections Only</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Surgeon will perform the periarticular injections:
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine
Intravenous sedation with midazolam and propofol.
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone</description>
        </group>
        <group group_id="E2">
          <title>Peri-Articular Injections and Adductor Canal Block</title>
          <description>Intra-Operatively
Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)
Adductor canal block technique:
Supine position, after IV sedation
Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches
Femoral artery will be identified in the adductor canal deep to the Sartorius muscle
15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone
Local anesthetic will be delivered periarterial between 12 and 6 o’clock
Intravenous sedation with midazolam and propofol.
First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc
Second superficial injection prior to closure. 20 ml 0.25% bupivacaine
Bupivacaine
Morphine
Methylprednisolone
Cefazolin
Normal saline
Midazolam
Propofol
Dexamethasone
8 MHz. Chiba needle, 22 G / 4 inches</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Birch</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>2127747377</phone>
      <email>birchg@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

